CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder

Medication Adherence Clinical Trial

— CoMBAT_OUD  

Official title:

CoMBAT Opioid Use Disorder: A Pilot Randomized Controlled Trial of a Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04240093
• Other study ID #: 1906002463
• Secondary ID: Junior Investiga
• Status: Completed
• Phase: N/A
• Start date: November 15, 2019
• Est. completion date: March 31, 2022

Study information

• Verified date: May 2023
• Source: Brown University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks primarily to test, in a two-arm randomized controlled trial (RCT), the feasibility, acceptability, and preliminary efficacy of CoMBAT OUD, an intervention that integrates Behavioral Activation (BA) and substance abuse and health navigation counseling for individuals who are receiving medications for opioid use disorder (i.e., methadone; suboxone) to help them improve engagement in care and opioid use treatment outcomes. Participants will be randomized 1:1 to two arms: (1) the CoMBAT intervention (2 sessions of substance abuse and health navigation counseling + 8 sessions of BA counseling); or the (3) the standard of care (SOC) comparison condition, including two equivalent substance abuse and health navigation counseling. Participants will be followed for 6 months post-randomization, with assessments at months 3 and 6.

Description:

Opioid use disorder (OUD) is a chronic, relapsing disease and a major source of morbidity and mortality in the United States. Medications for opioid use disorder (i.e., methadone; buprenorphine) have been shown to reduce opioid use in diverse populations; however, long-term use of these medications and engagement in care are often suboptimal. Depression has been shown to contribute to medication discontinuation and care disengagement. Behavioral activation (BA) therapy is an evidence-based, behavioral treatment that has been shown to be effective in treating comorbid depression and substance use in diverse populations with smoking, alcohol, stimulant, and poly-substance use disorder. BA utilizes therapeutic techniques that help patients gradually increase goal-directed, potentially rewarding and pleasurable activities while decreasing the intensity and frequency of adverse events and consequences in order to improve mood. Given that BA utilizes strategies that can support individuals in alleviating depression and build the capacity to navigate life challenges, pairing BA with medications for OUD could help to ensure continued engagement in care and improve OUD treatment outcomes.

This study, therefore, seeks to determine the feasibility of study procedures, enhance participant acceptability, and demonstrate preliminary efficacy of the CoMBAT (Combined Medication and Behavioral Activation Treatment) intervention. The investigators will enroll individuals currently being treated with methadone or buprenorphine for OUD in a pilot randomized controlled trial (RCT) of the CoMBAT intervention. Prior to randomization, participants will receive 2 health navigation and standard substance abuse counseling sessions. Participants will then be equally randomized to either: 1) the 8-session CoMBAT intervention; or 2) standard of care. The primary outcome is engagement in care. Secondary outcomes include self-reported days of opioid use and opioid-positive urinalysis. Intervention feasibility and acceptability will also be assessed. Participants will complete major assessment visits (survey and toxicology testing) at baseline and 3- and 6-months post-randomization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: March 31, 2022
• Est. primary completion date: February 18, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older

• Initiated medications for opioid use >= 30 day prior to screening

• Current depressive symptoms

• Plans to stay in Rhode Island or Massachusetts for at least 6-months

• Able to read, speak, and understand English

• Willing and able to provide informed consent

Exclusion Criteria:

• Does not plan to continue taking medications for opioid use disorder

• Unable to provide informed consent due to severe mental or physical illness, or substance intoxication at the time of interview

• Discovery of active suicidal ideation at the time of interview

• In the second or third trimester of pregnancy

Related Conditions & MeSH terms

• Disease
• Health Care Utilization
• Medication Adherence
• Opioid-Related Disorders
• Opioid-use Disorder
• Substance-Related Disorders

Intervention

Behavioral:
• Behavioral Activation (BA) Therapy
8 sessions of behavioral activation therapy
• Substance Abuse and Health Navigation Counseling
2 standard substance abuse and health navigation counseling

Other:
• Medications for Opioid Use Disorder
Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).

Locations

Country	Name	City	State
United States	Brown University	Providence	Rhode Island

Sponsors (5)

Lead Sponsor	Collaborator
Brown University	Boston University, National Institute of General Medical Sciences (NIGMS), Rhode Island Hospital, University of Massachusetts, Boston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Missed Medication Doses - Past 30 Days	Self-reported change in the number of missed methadone or buprenorphine doses in the past 30 days. Raw, unadjusted means at 6-month follow-up are reported.	Baseline, 3 month follow-up, and 6 month follow-up
Primary	Number of Missed Medication-related Visits - Past 30 Days	Self-reported change in the number of medication-related clinic visits missed in the past 30 days from baseline to follow-up.	Baseline, 3 month follow-up, and 6 month follow-up
Secondary	Fentanyl and Opiate-positive Urine Toxicology Screen	Fentanyl or opiate-positive urine screen (opiates refer to natural opioids such as heroin, morphine so buprenorphine, methadone, and other synthetic opioids are not included)	Baseline, 3 month follow-up, and 6 month follow-up

External Links

•   FRESH Research Lab